Otsuka Holdings Co Ltd - Company Profile
Powered by
All the data and insights you need on Otsuka Holdings Co Ltd in one report.
- Save hours of research time and resources with
our up-to-date Otsuka Holdings Co Ltd Strategy Report
- Understand Otsuka Holdings Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Otsuka Holdings Co Ltd (Otsuka) is a holding company, which operates various businesses such as pharmaceuticals, nutraceuticals, consumer products, and other businesses through its subsidiaries. It focuses on the research and development, manufacture, and sale of medicines for the treatment of cancer, cardiovascular diseases, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological conditions, and allergies. The company’s product portfolio includes pharmaceutical products, cosmedics, functional foods and beverages, fine chemicals, electronic equipment, functional chemicals, medical devices, and OTC products. It markets its products across North America, Europe, and Asia. Otsuka is headquartered in Minato-ku, Tokyo, Japan.
Otsuka Holdings Co Ltd premium industry data and analytics
Products and Services
Products | Services | Brands |
---|---|---|
Pharmaceuticals: | Transportation | Abilify |
Anti-psychotic | Warehousing | Sprycel |
Anti-platelet Agents | Busulfex | |
XYZ | XYZ | |
XYZ | XYZ | |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Acquisitions/Mergers/Takeovers | In December, the company's subsidiary, Pharmavite LLC, acquired Bonafide Health LLC. |
2023 | Plans/Strategy | In August, Taiho Pharmaceutical announced its plans to launch Lytgobi (futibatinib). |
2023 | Regulatory Approval | In May, Otsuka Pharmaceutical and H Lundbeck received approval for the supplemental new drug application from the US Food and Drug Administration for Rexulti (brexpiprazole) to treat agitation associated with dementia due to Alzheimer’s disease. |
Competitor Comparison
Key Parameters | Otsuka Holdings Co Ltd | Astellas Pharma Inc | Daiichi Sankyo Co Ltd | Chugai Pharmaceutical Co Ltd | Mitsubishi Tanabe Pharma Corp |
---|---|---|---|---|---|
Headquarters | Japan | Japan | Japan | Japan | Japan |
City | Minato-Ku | Chuo-Ku | Chuo-Ku | Chuo-Ku | Osaka |
State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Osaka |
No. of Employees | 34,388 | 14,484 | 17,435 | 7,604 | 6,697 |
Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Ichiro Otsuka | Chairman | Executive Board | 2015 | 59 |
Tatsuo Higuchi | Director; Chief Executive Officer; President | Executive Board | 2008 | 74 |
Yuko Makino | Director; Chief Financial Officer | Executive Board | 2019 | 63 |
Makoto Inoue | Director; Chief Operating Officer | Executive Board | 2024 | 66 |
Yoshiro Matsuo | Director; Executive Deputy President | Executive Board | 2022 | 64 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer